Alendronate
Based on 10 publication(s) in Google Scholar
Alendronate (Alendronate acid) is an orally active bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Alendronate induces skeletal alterations in the chicken embryonic development model. Alendronate can be used for osteoporosis research.
For research use only. We do not sell to patients.
- Purity : 98.0%
- CAS No.: 66376-36-1
- Formula: C4H13NO7P2
- Molecular Weight:249.10
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-11101
Alendronate sodium hydrateNitrogen-Containing Bisphosphonate -
HY-B0302
Etidronic acid -
HY-17502
SimvastatinHMGCR Inhibitor -
HY-13777
Zoledronic AcidAnti-resorptive Agant -
HY-B0148
Risedronic acidAnti-resorption Agent -
HY-B0589
AtorvastatinHMG-CoA Reductase Inhibitor -
HY-16566
KanamycinAntibacterial Agent -
HY-N0784
Ginkgolide BPlatelet Activating Factor Antagonist -
HY-14452
FatostatinSREBP Activation Inhibitor -
HY-16322
Minodronic acidFPP Synthase Inhibitor
Publications Citing Use of MedChemExpress (MCE) Alendronate
More- J Pharm Anal. 2025 Jul 31.
- Int J Mol Med. 2025 Dec;56(6):206. [Abstract]
- Cell Rep. 2022 Oct 25;41(4):111508. [Abstract]
- J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]
- Biochem Pharmacol. 2025 Aug 13;242(Pt 1):117234. [Abstract]
- Int J Mol Sci. 2024 Jul 16;25(14):7798. [Abstract]
- Am J Physiol Endocrinol Metab. 2024 Jul 1;327(1):E55-E68. [Abstract]
- J Biol Chem. 2019 Jul 19;294(29):11240-11247. [Abstract]
- Bone. 2025 Mar:192:117348. [Abstract]
- Pathol Res Pract. 2025 Sep:273:156138. [Abstract]
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Cell Imaging/Staining
-
Flow Cytometry
-
Flow Cytometry
-
Cell Imaging/Staining
Biological Activity
Description
IC50 & Target
[3]|
IL-6 |
NF-κB |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BMDM | IC50 |
4.22 μM
Compound: ALN
|
Inhibition of osteoclastogenesis in C57BL/6J mouse Bone marrow macrophage cells assessed as inhibition of RANKL-stimulated osteoclast formation measured after 6 days by tartrate-resistant acid phosphatase (TRAP) staining assay
Inhibition of osteoclastogenesis in C57BL/6J mouse Bone marrow macrophage cells assessed as inhibition of RANKL-stimulated osteoclast formation measured after 6 days by tartrate-resistant acid phosphatase (TRAP) staining assay
|
[PMID: 39185622] |
| HFF | IC50 |
108.8 μM
Compound: 45
|
In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells)
In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells)
|
[PMID: 15857119] |
| MCF7 | IC50 |
69.5 μM
Compound: Alendronate
|
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 to 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 to 48 hrs by SRB assay
|
[PMID: 33132173] |
| T-cell | EC50 |
0.9 μM
Compound: Alendronate
|
Effective concentration to activate gammadelta T cells
Effective concentration to activate gammadelta T cells
|
[PMID: 12383012] |
| T-cell | EC50 |
32 μM
Compound: 2
|
Effective concentration against human Gamma delta T cells
Effective concentration against human Gamma delta T cells
|
[PMID: 15828834] |
| T-cell | IC50 |
52 μM
Compound: 32
|
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL
|
[PMID: 14711309] |
| T-cell | IC50 |
53 μM
Compound: 32
|
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release
|
[PMID: 14711309] |
| Vero | IC50 |
25 μM
Compound: 1
|
Inhibition of Trypanosoma cruzi Amastigotes was determined in Vero cells culture and fetal calf serum
Inhibition of Trypanosoma cruzi Amastigotes was determined in Vero cells culture and fetal calf serum
|
[PMID: 11300872] |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Viable fertilized chick eggs (7 days)[3]
-
Dosage:1.5E-7 M, 1.5E-8 M, 1.5E-9 M, and 1.5E-10 M
-
Administration:intra-air cell injection, single dose at embryonic day 7, exposure for 4 days
-
Result:Showed an 87.5% viability rate and a 75% viability rate at 1.5E-10 M and other doses, respectively.
Significantly reduced bone morphometric indexes (bone volume (BV) and bone surface (BS)) and cortical thickness in a dose-dependent manner.
Significantly reduced dimensions and diminished mineralization in a concentration-dependent manner.
Significantly increased TNFRSF11B, NF-κB1 and IL-6 levels, and decreased TNFRSF11A, CTSK, COL1A2, SPP1, and SOST levels, compared to control.
Chemical Information
-
CAS No. 66376-36-1
-
Appearance Solid
-
Molecular Weight 249.10
-
Formula C4H13NO7P2
-
Color White to off-white
-
SMILES
OC(P(O)(O)=O)(CCCN)P(O)(O)=O
-
Synonyms
Alendronic acid; MK 217 free base; G-704650 Adronat free base
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
-
Int J Mol Med
Cynarin as a potent anti‑osteolytic agent: Targeting MAPK and Nrf2‑Keap1 pathways for osteoclast inhibition and bone protection. [Abstract]2025 Dec;56(6):206. PMID: 40999989 -
Cell Rep
Genome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2. [Abstract]2022 Oct 25;41(4):111508. PMID: 36288714 -
J Med Chem
Discovery of Novel Neo-Clerodane Derivatives as Potent Dual-Functional Antiosteoporosis Agents through Targeting Peroxisome Proliferator-Activated Receptor-γ. [Abstract]2024 Sep 12;67(17):15738-15755. PMID: 39185622
Alendronate purchased from MedChemExpress. Usage Cited in: J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]
Alendronate sodium hydrate (33 μM; 48 h) significantly restored mpx expression in Tg(drl:hoxa9) embryos.
Alendronate purchased from MedChemExpress. Usage Cited in: J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]
Alendronate sodium hydrate (33 μM; 48 h) recovered macrophage differentiation in Tg(drl:hoxa9) embryos.
Alendronate purchased from MedChemExpress. Usage Cited in: J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]
Flow cytometry analysis of CD14 and CD11b expression in U937 cells treated with different doses of Alendronate sodium hydrate (20-40 μM).
Alendronate purchased from MedChemExpress. Usage Cited in: J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]
Flow cytometry analysis of CD14 and CD11b expression in U937 cells treated with Alendronate sodium hydrate (30 μM; 3 d).
Alendronate purchased from MedChemExpress. Usage Cited in: J Med Chem. 2024 Sep 12;67(17):15738-15755. [Abstract]
Alendronate sodium hydrate (30 μM) induced chromatin condensation and increased the nucleocytoplasmic ratio in U937 cells, supporting the differentiation of these cells.
-
Biochem Pharmacol
Irisolidone enhances osteoblast differentiation via the AMPK-ULK1-autophagy Axis to accelerate osteoporotic fracture repair. [Abstract]2025 Aug 13;242(Pt 1):117234. PMID: 40816626 -
Int J Mol Sci
In Vivo Chemical Screening in Zebrafish Embryos Identified FDA-Approved Drugs That Induce Differentiation of Acute Myeloid Leukemia Cells. [Abstract]2024 Jul 16;25(14):7798. PMID: 39063039 -
Am J Physiol Endocrinol Metab
Mononuclear phagocyte morphologic response to chemoattractants is dependent on geranylgeranyl pyrophosphate. [Abstract]2024 Jul 1;327(1):E55-E68. PMID: 38717364 -
J Biol Chem
Mature osteoclast-derived apoptotic bodies promote osteogenic differentiation via RANKL-mediated reverse signaling. [Abstract]2019 Jul 19;294(29):11240-11247. PMID: 31167789 -
Bone
2025 Mar:192:117348. PMID: 39617111 -
Pathol Res Pract
Alendronate-functionalized ZIF-8 nanoplatform for targeted delivery of SHH siRNA and docetaxel to treat prostate cancer bone metastasis. [Abstract]2025 Sep:273:156138. PMID: 40694986
Solvent & Solubility
In Vitro:
H2O : 3.7 mg/mL (14.85 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 6.67 mg/mL (26.78 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Purity & Documentation
-
Data Sheet (287 KB)
-
SDS (476 KB)
- English - EN (476 KB)
- Français - FR (476 KB)
- Deutsch - DE (476 KB)
- Norwegian - NO (476 KB)
- Español - ES (476 KB)
- Swedish - SV (476 KB)
- Italian - IT (476 KB)
- Korean - KR (476 KB)
- Portuguese - PT (476 KB)
-
Handling Instructions (2659 KB)
References
[1]. Imai K. Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation. Clin Interv Aging. 2013;8:681-688. [Content Brief]
[2]. Sharpe M, et al. Alendronate: an update of its use in osteoporosis. Drugs. 2001;61(7):999-1039. [Content Brief]
[3]. de Campos WG, et al. Alendronate induces skeletal alterations in the chicken embryonic development model. Toxicol Appl Pharmacol. 2023 Oct 1;476:116673. [Content Brief]
Hot Topics
-
All
-
Topics
-
Most Recent
-
Oldest
-
Topics How NF-κB Writes Inflammatory Memory
How NF-κB writes inflammatory memory refers to the capacity of NF-κB signaling to convert transient inflammatory stimuli into persistent transcriptional, epigenetic, and cellular states that influence future immune responses.
2026-06-18
-
Topics The STING-NF-κB Anti-Infection Signaling Cascade
STING-NF-κB anti-infection signaling describes a cytosolic DNA-sensing cascade that links microbial DNA detection to inflammatory cytokine production and host defense.
2026-06-18
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 4.0145 mL | 20.0723 mL | 40.1445 mL | 100.3613 mL |
| 5 mM | 0.8029 mL | 4.0145 mL | 8.0289 mL | 20.0723 mL | |
| 10 mM | 0.4014 mL | 2.0072 mL | 4.0145 mL | 10.0361 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Alendronate Related Classifications
HY-B0631 Related Classifications
Powered by Bioz